Skip to content
Menu

RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $52

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

RBC Capital analyst Kendall Au maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $70 to $52.

RBC Capital analyst Kendall Au maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $70 to $52.

Read at benzinga.com

← All stock news